The role of oxidative stress in Huntington's disease: Are antioxidants good therapeutic candidates?

Current Drug Targets

Volumn 15, Issue 4, 2014, Pages 454-468

  Gil Mohapel, Joana ^a   Brocardo, Patricia S ^a,b   Christie, Brian R ^a,c,d  

^a UNIVERSITY OF VICTORIA   (Canada)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antioxidant; Clinical trial; Huntington's disease; Oxidative stress; Reactive oxygen species; Transgenic mice

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CATALASE; CLIOQUINOL; CREATINE; CURCUMIN; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDROGEN PEROXIDE; ICOSAPENTAENOIC ACID; IDEBENONE; MINOCYCLINE; N (7 HYDROXY 2,2,4,6 TETRAMETHYL 1 INDANYL) 4 (3 METHOXYPHENYL) 1 PIPERAZINEACETAMIDE; REACTIVE OXYGEN METABOLITE; REMACEMIDE; SUPEROXIDE DISMUTASE; TAUROURSODEOXYCHOLIC ACID; TRANSCRIPTION FACTOR NRF2; UBIDECARENONE;

BLOOD BRAIN BARRIER; CELL DEATH; ENZYME ACTIVITY; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; LIPID PEROXIDATION; MITOCHONDRION; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANIMALS; ANTIOXIDANTS; CELL DEATH; CLINICAL TRIALS AS TOPIC; CREATINE; FATTY ACIDS, ESSENTIAL; HUMANS; HUNTINGTON DISEASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; UBIQUINONE;

EID: 84896356369     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140115113734     Document Type: Review

References (170)

1. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-384.
2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
3. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-3.
4. Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008; 27: 2803-2820.
5. Folstein S, Abbott MH, Chase GA, Jensen BA, Folstein MF. The association of affective disorder with Huntington's disease in a case series and in families. Psychol Med 1983; 13: 537-42.
6. Dewhurst K, Oliver JE, McKnight AL. Socio-psychiatric consequences of Huntington's disease. Br J Psychiatry 1970; 116: 255-8.
7. Jensen P, Sorensen SA, Fenger K, Bolwig TG. A study of psychiatric morbidity in patients with Huntington's disease, their relatives, and controls. Admissions to psychiatric hospitals in Denmark from 1969 to 1991. Br J Psychiatry 1993; 163: 790-7.
8. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011; 10: 31-42.
9. Brocardo PS, Gil-Mohapel J. Therapeutic strategies for Huntington's disease: from the bench to the clinic. Current Psychopharmacology 2012; 1: 137-54.
10. Brocardo PS, Gil-Mohapel J. From preclinical to clinical trials: an update on potential therapies for Huntington's disease. Curr Psychopharmacol 2013; 2: 113-31.
11. Gil JM, Rego AC. The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease. Brain Res Rev 2009; 59: 410-31.
12. Gil-Mohapel JM. Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice. CNS Neurosci Ther. 2012; 18: 77-86.
13. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-81.
14. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991; 91: 31S-8S.
15. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186: 1-85.
16. Gao HM, Liu B, Zhang W, Hong JS. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 2003; 17: 1954-6.
17. Infanger DW, Sharma RV, Davisson RL. NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal 2006; 8: 1583-96.
18. Zadak Z, Hyspler R, Ticha A. Antioxidants and vitamins in clinical conditions. Physiol Res 2009; 58: S13-S17.
19. Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans 2007; 35: 1147-50.
20. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994; 63: 793-807.
21. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609-23.
22. Sokoloff L. Energetics of functional activation in neural tissues. Neurochem Res 1999; 24: 321-9.
23. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
24. Halliwell B, Gutteridge JM. The definition and measurement of antioxidants in biological systems. Free Radic Biol Med 1995; 18: 125-6.
25. Aliev G, Obrenovich ME, Reddy VP, et al. Antioxidant therapy in Alzheimer's disease: theory and practice. Mini Rev Med Chem. 2008; 8: 1395-406.
26. Fridovich I. Superoxide anion radical (O2-.), superoxide dismutases, and related matters. J Biol Chem 1997; 272: 18515-7.
27. Percy ME. Catalase: an old enzyme with a new role? Can J Biochem Cell Biol 1984; 62: 1006-14.
28. Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol 2006; 141: 312-22.
29. Halliwell B. Free radicals and antioxidants-quo vadis? Trends Pharmacol Sci 2011; 32: 125-30.
30. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-85.
31. Stack EC, Matson WR, Ferrante RJ. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann N Y Acad Sci 2008; 1147: 79-92.
32. Tasset I, Sanchez F, Tunez I. The molecular bases of Huntington's disease: the role played by oxidative stress. Rev Neurol 2009; 49: 424-9.
33. Deckel AW, Tang V, Nuttal D, Gary K, Elder R. Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice. Brain Res 2002; 939: 76-86.
34. Deckel AW. Nitric oxide and nitric oxide synthase in Huntington's disease. J Neurosci Res 2001; 64: 99-107.
35. Perez-Severiano F, Escalante B, Vergara P, Rios C, Segovia J. Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation. Brain Res 2002; 951: 36-42.
36. Tabrizi SJ, Workman J, Hart PE, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 2000; 47: 80-6.
37. Santamaria A, Perez-Severiano F, Rodriguez-Martinez E, et al. Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease. Neurochem Res 2001; 26: 419-24.
38. Rebec GV, Barton SJ, Ennis MD. Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene. J Neurosci 2002; 22: RC202.
39. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
40. Perez-Severiano F, Santamaria A, Pedraza-Chaverri J, Medina-Campos ON, Rios C, Segovia J. Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation. Neurochem Res 2004; 29: 729-33.
41. Lee J, Kosaras B, Del Signore SJ, et al. Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice. Acta Neuropathol 2011; 121: 487-98.
42. Pitts A, Dailey K, Newington JT, et al. Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin. J Biol Chem 2012; 287: 22717-29.
43. Alam ZI, Halliwell B, Jenner P. No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease. J Neurochem 2000; 75: 840-6.
44. Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006; 8: 2061-73.
45. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999; 9: 147-63.
46. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F. Oxidative stress and plasma aminopeptidase activity in Huntington's disease. J Neural Transm 2010; 117: 325-332.
47. Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med 2008; 45: 667-78.
48. Chen CM, Wu YR, Cheng ML, et al. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem Biophys Res Commun 2007; 359: 335-40.
49. del Hoyo P, Garcia-Redondo A, de Bustos F, et al. Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease. Neurochem Res 2006; 31: 1103-09.
50. Brennan WAJr, Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985; 44: 1948-50.
51. Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997; 41: 646-53.
52. Butterworth J, Yates CM, Reynolds GP. Distribution of phosphateactivated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J Neurol Sci 1985; 67: 161-71.
53. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996; 39: 385-9.
54. Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, Schapira AH. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990; 336: 749.
55. Stahl WL, Swanson PD. Biochemical abnormalities in Huntington's chorea brains. Neurology 1974; 24: 813-9.
56. Parker WDJr, Boyson SJ, Luder AS, Parks JK. Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 1990; 40: 1231-4.
57. Powers WJ, Haas RH, Le T, et al. Normal platelet mitochondrial complex I activity in Huntington's disease. Neurobiol Dis 2007; 27: 99-101.
58. Arenas J, Campos Y, Ribacoba R, et al. Complex I defect in muscle from patients with Huntington's disease. Ann Neurol 1998; 43: 397-400.
59. Turner C, Cooper JM, Schapira AH. Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov Disord 2007; 22: 1715-21.
60. Ciammola A, Sassone J, Alberti L, et al. Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ 2006; 13: 2068-78.
61. Panov AV, Gutekunst CA, Leavitt BR, et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002; 5: 731-6.
62. Sawa A, Wiegand GW, Cooper J, et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat lengthdependent mitochondrial depolarization. Nat Med. 1999; 5: 1194-8.
63. Squitieri F, Cannella M, Sgarbi G, et al. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev 2006; 127: 217-20.
64. Liu CS, Cheng WL, Kuo SJ, Li JY, Soong BW, Wei YH. Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. J Neurol Sci 2008; 264: 18-21.
65. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993; 13: 4181-92.
66. Borlongan CV, Koutouzis TK, Randall TS, Freeman TB, Cahill DW, Sanberg PR. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res Bull 1995; 36: 549-56.
67. Brouillet E, Jenkins BG, Hyman BT, et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993; 60: 356-9.
68. Brouillet E, Guyot MC, Mittoux V, et al. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem 1998; 70: 794-805.
69. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience. 1997; 79(1): 45-56.
70. Koutouzis TK, Borlongan CV, Scorcia T, et al. Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Res 1994; 646(2): 242-6.
71. Brouillet E, Hantraye P. Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr Opin Neurol 1995; 8: 469-73.
72. Palfi S, Ferrante RJ, Brouillet E, et al. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 1996; 16: 3019-25.
73. Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 1217-40.
74. Perez-De La Cruz V, Elinos-Calderon D, Robledo-Arratia Y, et al. Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease. Behav Brain Res 2009; 199: 210-7.
75. Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 1993; 61: 1147-50.
76. Browne SE. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci 2008; 1147: 358-82.
77. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 2004; 13: 1407-20.
78. Oliveira JM, Chen S, Almeida S, et al. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci 2006; 26: 11174-86.
79. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
80. Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006; 4: 349-62.
81. Kim J, Moody JP, Edgerly CK, et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet 2010; 19: 3919-35.
82. Sarsilmaz M, Songur A, Ozyurt H, et al. Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 253-9.
83. Sarsimaz M, Songur A, Kus I, et al. The regulatory role of dietary ω-3 essential fatty acids on oxidant/antioxidant balance in rat hippocampus. Neurosci Res Commun 2003; 33: 114-23.
84. Songur A, Sarsilmaz M, Sogut S, et al. Hypothalamic superoxide dismutase, xanthine oxidase, nitric oxide, and malondialdehyde in rats fed with fish omega-3 fatty acids. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 693-8.
85. Lim SY, Suzuki H. Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. J Nutr 2000; 130: 1629-32.
86. Uauy R, Dangour AD. Nutrition in brain development and aging: role of essential fatty acids. Nutr Rev 2006; 64: S24-S33, discussion S72-S91.
87. Dyall SC, Michael GJ, Michael-Titus AT. Omega-3 fatty acids reverse age-related decreases in nuclear receptors and increase neurogenesis in old rats. J Neurosci Res 2010; 88: 2091-102.
88. Hagen TM, Ingersoll RT, Lykkesfeldt J, et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. 1999; 13: 411-18.
89. Bas O, Songur A, Sahin O, et al. The protective effect of fish n-3 fatty acids on cerebral ischemia in rat hippocampus. Neurochem Int 2007; 50: 548-54.
90. Connell BJ, Saleh M, Khan BV, Saleh TM. Lipoic acid protects against reperfusion injury in the early stages of cerebral ischemia. Brain Res 2011; 1375: 128-36.
91. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 2004; 21: 1457-67.
92. Hashimoto M, Hossain S, Shimada T, et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 2002; 81: 1084-1091.
93. Hashimoto M, Tanabe Y, Fujii Y, Kikuta T, Shibata H, Shido O. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid betainfused rats. J Nutr 2005; 135: 549-55.
94. Green KN, Martinez-Coria H, Khashwji H, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 2007; 27: 4385-95.
95. Tanriover G, Seval-Celik Y, Ozsoy O, et al. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease. Folia Histochem Cyto 2010; 48: 434-41.
96. Clifford JJ, Drago J, Natoli AL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002; 109: 81-8.
97. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 2001; 12: 3371-73.
98. Arivazhagan P, Ramanathan K, Panneerselvam C. Effect of DLalpha-lipoic acid on mitochondrial enzymes in aged rats. Chem Biol Interact 2001; 138: 189-98.
99. Suzuki T, Fukuo K, Suhara T, et al. Eicosapentaenoic acid protects endothelial cells against anoikis through restoration of cFLIP. Hypertension 2003; 42: 342-8.
100. Babcock T, Helton WS, Espat NJ. Eicosapentaenoic acid (EPA): an antiinflammatory omega-3 fat with potential clinical applications. Nutrition 2000; 16: 1116-8.
101. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004; 6: 461-7.
102. Froyland L, Madsen L, Vaagenes H, et al. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J Lipid Res 1997; 38: 1851-8.
103. Slow EJ, van Raamsdonk J, Rogers D, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003; 12: 1555-67.
104. Van Raamsdonk JM, Pearson J, Rogers DA, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 2005; 196: 266-272.
105. Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebocontrolled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002; 13: 29-33.
106. Puri BK, Bydder GM, Counsell SJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002; 13: 123-6.
107. Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005; 65: 286-92.
108. Puri BK, Bydder GM, Manku MS, Clarke A, Waldman AD, Beckmann, CF. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. J Int Med Res 2008; 36: 896-905.
109. Murck H, Manku M. Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res Bull 2007; 72: 159-64.
110. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008; 65: 1582-9.
111. Hemmer W, Wallimann T. Functional-Aspects of Creatine-Kinase in Brain. Dev Neurosci-Basel 1993; 15: 249-60.
112. Kim J, Amante DJ, Moody JP, et al. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim Biophys Acta 2010; 1802: 673-81.
113. Lin YS, Chen CM, Soong BW, et al. Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. J Clin Invest. 2011; 121: 1519-23.
114. Zhang SF, Hennessey T, Yang L, Starkova NN, Beal MF, Starkov AA. Impaired Brain Creatine Kinase Activity in Huntington's Disease. Neurodegener Dis 2011; 8: 194-201.
115. Lin YS, Cheng TH, Chang CP, Chen HM, Chern Y. Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease. Biochim Biophys Acta 2013;1832: 742-53.
116. Lawler JM, Barnes WS, Wu G, Song W, Demaree S. Direct antioxidant properties of creatine. Biochem Biophys Res Commun 2002; 290: 47-52.
117. Beal MF. Neuroprotective effects of creatine. Amino Acids 2011; 40: 1305-13.
118. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000; 20: 4389-97.
119. Dedeoglu A, Kubilus JK, Yang L, et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem 2003; 85: 1359-67.
120. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001; 8: 479-91.
121. Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003; 61: 925-30.
122. Tabrizi SJ, Blamire AM, Manners DN, et al. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003; 61: 141-2.
123. Tabrizi SJ, Blamire AM, Manners DN, et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 2005; 64: 1655-6.
124. Bender A, Auer DP, Merl T, et al. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol 2005; 252: 36-41.
125. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006; 66: 250-2.
126. Echtay KS, Winkler E, Klingenberg M. Coenzyme Q is an obligatory cofactor for uncoupling protein function. Nature 2000; 408: 609-13.
127. Shults CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003; 10: 1917-21.
128. Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors 1999; 9: 261-6.
129. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 2007; 37: 31-7.
130. Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets 2010; 11: 111-21.
131. Smith KM, Matson S, Matson WR, et al. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta 2006; 1762: 616-26.
132. Menalled LB, Patry M, Ragland N, et al. Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 2010; 5: e9793.
133. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002; 22: 1592-9.
134. Schilling G, Becher MW, Sharp AH, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant Nterminal fragment of huntingtin. Hum Mol Genet 1999; 8: 397-407.
135. Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 2009; 109: 1427-39.
136. Sancho M, Herrera AE, Gortat A, et al. Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1. Hum Mol Genet 2011; 20: 3545-53.
137. Scarabelli TM, Stephanou A, Pasini E, et al. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol 2004; 43: 865-74.
138. Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Antiamyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 2001; 487: 404-7.
139. Stack EC, Smith KM, Ryu H, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006;1762: 373-80.
140. Hickey MA, Zhu C, Medvedeva V, Franich NR, Levine MS, Chesselet MF. Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Mol Cell Neurosci 2012; 49: 149-57.
141. Hickey MA, Kosmalska A, Enayati J, et al. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 2008; 157: 280-95.
142. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knockin mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 2003; 465: 11-26.
143. Feigin A, Kieburtz K, Como P, et al. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996; 11: 321-3.
144. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57: 397-404.
145. Kieburtz K, Feigin A, McDermott M, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 1996; 11: 273-7.
146. Rebec GV, Barton SJ, Marseilles AM, Collins K. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 2003; 14: 1263-5.
147. Rebec GV, Conroy SK, Barton SJ. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 2006; 137: 327-36.
148. Miller BR, Dorner JL, Bunner KD, et al. Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease. J Neurochem 2012; 121: 629-38.
149. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 2002; 99: 10671-6.
150. Iannicola C, Moreno S, Oliverio S, Nardacci R, Ciofi-Luzzatto A, Piacentini M. Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. J Neurochem 2000; 75: 830-9.
151. Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 2000; 97: 8093-7.
152. Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci 2003; 23: 2193-202.
153. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem 2003; 86: 267-72.
154. Stack C, Ho D, Wille E, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 2010; 49: 147-58.
155. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114: 1953-75.
156. Nguyen T, Hamby A, Massa SM. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102: 11840-5.
157. Begum AN, Jones MR, Lim GP, et al. Curcumin structurefunction, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008; 326: 196-208.
158. Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001; 22: 993-1005.
159. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21: 8370-7.
160. Hickey MA, Zhu C, Medvedeva V, et al. Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Mol Neurodegener 2012; 7: 12.
161. Baum L, Cheung SK, Mok VC, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 2007; 56: 509-14.
162. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008; 28: 110-13.
163. Peyser CE, Folstein M, Chase GA, et al. Trial of d-alphatocopherol in Huntington's disease. Am J Psychiatry 1995; 152: 1771-5.
164. Ranen NG, Peyser CE, Coyle JT, et al. A controlled trial of idebenone in Huntington's disease. Mov Disord 1996; 11: 549-54.
165. Huntington Study Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology 1998; 50: 1366-73.
166. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis 2008; 15: 473-93.
167. Carter RJ, Hunt MJ, Morton AJ. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov Disord 2000; 15: 925-937.
168. Olanow CW, Wunderle KB, Kieburtz K. Milestones in movement disorders clinical trials: advances and landmark studies. Mov Disord 2011; 26: 1003-14.
169. Aylward EH, Rosenblatt A, Field K, et al. Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Res Bull 2003; 62: 137-41.
170. Ravina B, Romer M, Constantinescu R, et al. The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord 2008; 23: 1223-7.